17-29968909-A-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_198529.4(EFCAB5):c.309A>T(p.Glu103Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000469 in 1,576,428 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_198529.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EFCAB5 | NM_198529.4 | c.309A>T | p.Glu103Asp | missense_variant | 4/23 | ENST00000394835.8 | NP_940931.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EFCAB5 | ENST00000394835.8 | c.309A>T | p.Glu103Asp | missense_variant | 4/23 | 1 | NM_198529.4 | ENSP00000378312 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000283 AC: 43AN: 152180Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000129 AC: 25AN: 193328Hom.: 0 AF XY: 0.000136 AC XY: 14AN XY: 103092
GnomAD4 exome AF: 0.000489 AC: 696AN: 1424248Hom.: 0 Cov.: 31 AF XY: 0.000457 AC XY: 322AN XY: 704736
GnomAD4 genome AF: 0.000283 AC: 43AN: 152180Hom.: 0 Cov.: 32 AF XY: 0.000202 AC XY: 15AN XY: 74350
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 16, 2022 | The c.309A>T (p.E103D) alteration is located in exon 4 (coding exon 4) of the EFCAB5 gene. This alteration results from a A to T substitution at nucleotide position 309, causing the glutamic acid (E) at amino acid position 103 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at